MGX Profile
Metagenomi, Inc. is a pioneering gene editing biotechnology company dedicated to advancing therapeutic solutions through its metagenomics-derived genome editing toolbox. Founded in 2016 and headquartered in Emeryville, California, Metagenomi specializes in developing cutting-edge gene editing technologies designed to address a broad range of medical conditions. The company's portfolio includes a variety of genome editing tools such as programmable nucleases, base editors, and advanced RNA and DNA-mediated integration systems. Notable among these are the prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases (CRISPR-associated transposases), which are designed to enable precise genetic modifications for therapeutic purposes.
Metagenomi has established significant strategic partnerships to enhance its gene editing capabilities and expand its therapeutic applications. The company holds a strategic collaboration and license agreement with ModernaTX, Inc., focused on developing novel genome editing systems for in vivo human therapeutic applications. This collaboration aims to leverage Metagenomi's advanced gene editing technologies to create new treatments that can be directly administered to patients. Additionally, Metagenomi has a development, option, and license agreement with Affini-T Therapeutics, Inc., which is centered on the development and commercialization of gene-edited T-cell receptor-based therapies. These therapies are intended for the treatment, prevention, or diagnosis of various types of human cancer.
Further extending its reach, Metagenomi has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. This partnership is aimed at researching, developing, and commercializing investigational medicines that utilize Metagenomi’s genome editing technologies. The collaboration seeks to explore new therapeutic avenues and enhance the precision of gene-based treatments, contributing to advancements in personalized medicine and targeted therapies.
With its innovative gene editing toolbox and robust strategic alliances, Metagenomi is at the forefront of biotechnology advancements. The company's commitment to developing transformative therapeutic solutions through its state-of-the-art technologies positions it as a key player in the gene editing field. Metagenomi’s ongoing research and collaborations underscore its role in driving progress toward effective and precise genetic therapies for a wide range of medical conditions.
|
